Emergent BioSolutions (NYSE:EBS) Now Covered by Analysts at StockNews.com

Stock analysts at StockNews.com assumed coverage on shares of Emergent BioSolutions (NYSE:EBS – Get Rating) in a research note issued on Thursday. The brokerage set a “sell” rating on the biopharmaceutical company’s stock.

Separately, TheStreet cut Emergent BioSolutions from a “c-” rating to a “d” rating in a report on Monday, February 27th. One research analyst has rated the stock with a sell rating, four have assigned a hold rating and one has issued a buy rating to the stock. According to MarketBeat, the stock currently has an average rating of “Hold” and a consensus target price of $36.75.

Emergent BioSolutions Price Performance

Emergent BioSolutions stock opened at $9.65 on Thursday. The business’s 50-day simple moving average is $12.98 and its 200 day simple moving average is $15.71. The stock has a market cap of $483.85 million, a price-to-earnings ratio of -2.15 and a beta of 0.94. Emergent BioSolutions has a 12-month low of $9.17 and a 12-month high of $45.14. The company has a quick ratio of 0.70, a current ratio of 0.98 and a debt-to-equity ratio of 0.32.

Emergent BioSolutions (NYSE:EBS – Get Rating) last issued its earnings results on Monday, February 27th. The biopharmaceutical company reported ($0.31) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.31 by ($0.62). Emergent BioSolutions had a negative return on equity of 7.57% and a negative net margin of 19.97%. The company had revenue of $330.70 million for the quarter, compared to the consensus estimate of $298.23 million. During the same quarter last year, the business posted $4.50 EPS. Emergent BioSolutions’s quarterly revenue was down 54.3% on a year-over-year basis. As a group, research analysts anticipate that Emergent BioSolutions will post -0.07 earnings per share for the current year.

Institutional Investors Weigh In On Emergent BioSolutions

A number of hedge funds have recently modified their holdings of EBS. BlackRock Inc. grew its stake in Emergent BioSolutions by 8.1% in the first quarter. BlackRock Inc. now owns 8,731,904 shares of the biopharmaceutical company’s stock valued at $358,533,000 after purchasing an additional 655,003 shares in the last quarter. Vanguard Group Inc. grew its stake in Emergent BioSolutions by 2.0% in the third quarter. Vanguard Group Inc. now owns 5,191,486 shares of the biopharmaceutical company’s stock valued at $108,969,000 after purchasing an additional 101,059 shares in the last quarter. State Street Corp grew its stake in Emergent BioSolutions by 4.0% in the third quarter. State Street Corp now owns 4,316,310 shares of the biopharmaceutical company’s stock valued at $90,599,000 after purchasing an additional 165,678 shares in the last quarter. Dimensional Fund Advisors LP grew its stake in Emergent BioSolutions by 33.4% in the first quarter. Dimensional Fund Advisors LP now owns 1,368,661 shares of the biopharmaceutical company’s stock valued at $56,199,000 after purchasing an additional 342,964 shares in the last quarter. Finally, Man Group plc grew its stake in Emergent BioSolutions by 34.3% in the fourth quarter. Man Group plc now owns 879,448 shares of the biopharmaceutical company’s stock valued at $10,386,000 after purchasing an additional 224,729 shares in the last quarter. Institutional investors and hedge funds own 80.44% of the company’s stock.

About Emergent BioSolutions

(Get Rating)

Emergent BioSolutions Inc engages in the development, manufacture, and commercialization of medical countermeasures. It offers products for civilian and military populations that address accidental, intentional, and naturally occurring public health threats. The firm’s products include ACAM2000, BioThrax, Raxibacuma, Vaxchora, and VIGIV.